Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by Boston Scientific Corporation
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT01775735
First received: January 23, 2013
Last updated: November 12, 2013
Last verified: November 2013
  Purpose

The primary objective of this study is to evaluate the safety and efficacy of occipital nerve stimulation (ONS) using the Boston Scientific Corporation (BSC) Precision™ System in the management of intractable chronic migraine, when used in conjunction with anti-migraine medications.


Condition Intervention
Migraine Disorders
Device: Occipital nerve stimulator

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Occipital Nerve Stimulation (ONS) for Migraine OPTIMISE

Resource links provided by NLM:


Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Change in the number of moderate-to-severe headache days per month [ Time Frame: from Baseline to 6 months post-randomization ] [ Designated as safety issue: No ]

    A moderate-to-severe headache day will be defined as any calendar day with:

    1. headache pain that lasts ≥4 hours AND peak severity of moderate or severe intensity

      OR

    2. a subject taking a triptan or ergot, regardless of headache pain duration or severity

    The Baseline number will be calculated as the total count of eDiary calendar days which meet the definition of a moderate-to-severe headache day during the first 30 calendar days of eDiary entries. The 6 months post-randomization number will be calculated as the total count of eDiary calendar days which meet the definition of a moderate-to-severe headache day during the 30 calendar days of eDiary entries immediately preceding the subject's 6-Month Visit.



Secondary Outcome Measures:
  • Moderate-to-severe headache frequency response [ Time Frame: 6 months post-randomization ] [ Designated as safety issue: No ]
    A responder will be defined as any subject achieving ≥50% reduction in the total count of moderate-to-severe headache days from the first 30 calendar days of eDiary entries to the 30 calendar days of eDiary entries immediately preceding the subject's 6-Month Visit.

  • Conversion to <15 moderate-to-severe headache days per month [ Time Frame: 6 months post-randomization ] [ Designated as safety issue: No ]
    A conversion subject will be defined as any subject with <15 total count of moderate-to-severe headache days during the 30 calendar days of eDiary entries immediately preceding the subject's 6-Month Visit.

  • Change in average number of moderate-to-severe headache hours per day [ Time Frame: from Baseline to 6 months post-randomization ] [ Designated as safety issue: No ]
    The number of moderate-to-severe headache hours for a given day will be defined as the number of hours in the corresponding eDiary entry that the subject spent with a headache with a peak intensity of moderate or severe. A calendar day with a peak intensity of mild will have 0 moderate-to-severe headache hours.

  • Change in daily headache intensity [ Time Frame: from Baseline to 6 months post-randomization ] [ Designated as safety issue: No ]
    Daily headache intensity will be calculated based on the Average Intensity question, collected using the eDiary, starting at the beginning of the 30-day Baseline eDiary period and ending at 6 months post-randomization.

  • Headache intensity response (30%) [ Time Frame: 6 months post-randomization ] [ Designated as safety issue: No ]
    For this endpoint, a responder will be defined as any subject achieving ≥30% reduction in daily headache intensity from the first 30 calendar days of eDiary entries to the 30 calendar days of eDiary entries immediately preceding the subject's 6-Month Visit.

  • Change in headache impact [ Time Frame: from Baseline to 6 months post-randomization ] [ Designated as safety issue: No ]
    Headache impact will be based on headache impact test (HIT-6) questionnaire, completed by the subject at the Baseline and 6-Month Visits.

  • Change in migraine-specific quality of life [ Time Frame: from Baseline to 6 months post-randomization ] [ Designated as safety issue: No ]
    Migraine-specific quality-of-life (MSQ) will be based on MSQ v2.1 questionnaire completed by the subject at the Baseline and 6-Month Visits.

  • Subject satisfaction with treatment [ Time Frame: 6 months post-randomization ] [ Designated as safety issue: No ]
    Subject satisfaction with treatment will be based on a modified treatment satisfaction questionnaire (TSQM-9) completed by the subject at the Baseline and 6-Month Visits. Subject satisfaction with treatment will be calculated as the total TSQM-9 score across all the domains of the questionnaire.

  • Rate of adverse events (AEs) [ Time Frame: 6 months post-randomization ] [ Designated as safety issue: Yes ]
    An adverse event is any untoward medical occurrence, unintended disease or injury, or any untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other persons, whether or not related to the investigational medical device.


Estimated Enrollment: 180
Study Start Date: January 2013
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Group A
The treatment device is an occipital nerve stimulator, specifically the BSC Precision™ ONS System
Device: Occipital nerve stimulator
Electrical stimulation of the greater occipital nerve
Other Name: Boston Scientific Precision System
Active Comparator: Treatment Group B
The treatment device is on occipital nerve stimulator, specifically the BSC Precision™ ONS System
Device: Occipital nerve stimulator
Electrical stimulation of the greater occipital nerve
Other Name: Boston Scientific Precision System

Detailed Description:

Initial reports of managing migraine headache with ONS described a technique in which electrical leads were implanted in the subcutaneous space transverse to the occipital nerve, in the back of the head, under x-ray guidance. The leads were tunneled under the skin to an implantable pulse generator (IPG) implanted in the chest wall or abdomen. The OPTIMISE Trial is designed to be a pivotal study of the Boston Scientific PRECISION neurostimulation system, when the system is used for ONS. The PRECISION System has been previously been approved for Spinal Cord Stimulation (SCS).

  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Onset of chronic migraine at least 6 months prior to start of Screening determined by a well-documented history
  • Evidence of intractability
  • Posterior-dominant head pain
  • Stable pattern of headache symptoms for at least 6 months prior to the beginning of Screening
  • Onset of migraine before the age of 50
  • If female of childbearing potential: not pregnant, as evidenced by a negative pregnancy test

Key Exclusion Criteria:

  • Diagnosed with any major psychiatric disorder not specifically listed in Key Exclusion Criteria 2-4 (e.g. multiple personality disorder, schizophrenia)
  • Untreated panic disorder
  • Untreated major depression evidenced by a PHQ-9 score >20
  • Untreated generalized anxiety disorder evidenced by a GAD-7 score ≥15
  • Currently diagnosed with severe personality disorder
  • A female of childbearing potential planning to get pregnant during the course of the study or not using adequate contraception
  • Participating in another drug, device, or biologics trial within 3 months prior to Screening
  • A terminal illness associated with survival <24 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01775735

Contacts
Contact: Ann Masuda, M.S. 661-949-4726 Ann.Masuda@bsci.com
Contact: Diane Bowers 661-949-4175 Diane.Bowers@bsci.com

Locations
United States, California
Boston Scientific Clinical Research Information Toll Free Number Recruiting
Valencia, California, United States, 91355
Contact    855-213-9890    BSNClinicalTrials@bsci.com   
Principal Investigator: Roger K. Cady, M.D.         
Principal Investigator: Benjamin A. Lampert, M.D.         
Principal Investigator: Brian M. Grosberg, M.D.         
Principal Investigator: Alon Y. Mogilner, M.D., Ph.D.         
Principal Investigator: Alexander Feoktistov, M.D., Ph.D.         
Principal Investigator: Konstantin V. Slavin, M.D.         
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Principal Investigator: Richard Lipton, MD Albert Einstein College of Medicine of Yeshiva University
  More Information

No publications provided

Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT01775735     History of Changes
Other Study ID Numbers: G120051, CDM00046436
Study First Received: January 23, 2013
Last Updated: November 12, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Boston Scientific Corporation:
headache
pain
chronic

Additional relevant MeSH terms:
Migraine Disorders
Brain Diseases
Central Nervous System Diseases
Headache Disorders
Headache Disorders, Primary
Nervous System Diseases

ClinicalTrials.gov processed this record on November 27, 2014